Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

The transaction will allow Lilly to expand its pain management pipeline with the addition of STC-004, a Phase 2-ready Nav1.8 inhibitor being studied for the treatment of pain.

The sale agreement will see Eli Lilly pay up to $1bn to buy SiteOne, ... The acquisition adds to Eli Lilly’s pain pipeline, which includes four candidates. A Phase I trial (ACTRN12624000642583) ...

LLY’s Zacks Rank. Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.. Only $1 to See All Zacks' Buys and Sells ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.